In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology

Transfusion

Volumn 50, Issue 10, 2010, Pages 2210-2219

  Ostrowski, Sisse R ^a,b   Bochsen, Louise ^a,b   Salado Jimena, José A ^a,b   Ullum, Henrik ^a,b   Reynaerts, Inge ^a,b   Goodrich, Raymond P ^a,b   Johansson, Pär I ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b CaridianBCT Biotechnologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; CD63 ANTIGEN; DUAL SPECIFICITY PHOSPHATASE 2; GLYCOPROTEIN IB; GLYCOPROTEIN IB ALPHA; LIPOCORTIN 5; PADGEM PROTEIN; THROMBOCYTE CONCENTRATE;

ARTICLE; BLOOD GAS ANALYSIS; BUFFY COAT PLATELET; CONTROLLED STUDY; FLOW CYTOMETRY; GLUCOSE INTAKE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; KINETICS; PATHOGEN REDUCTION TECHNOLOGY; PROTEIN EXPRESSION; QUALITY CONTROL; RISK REDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE METABOLISM; THROMBOCYTE PRESERVATION;

BLOOD BUFFY COAT; BLOOD PLATELETS; BLOOD PRESERVATION; BLOOD-BORNE PATHOGENS; FLOW CYTOMETRY; HUMANS; PHOTOSENSITIZING AGENTS; RIBOFLAVIN; ULTRAVIOLET RAYS;

EID: 78649484614     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02681.x     Document Type: Article

References (38)

1. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA 2003;289:959-62.
2. Allain JP, Bianco C, Blajchman MA, Brecher ME, Busch M, Leiby D, Lin L, Stramer S. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005;19:110-26.
3. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006;35:5-17.
4. Maurer-Spurej E, Chipperfield K. Past and future approaches to assess the quality of platelets for transfusion. Transfus Med Rev 2007;21:295-306.
5. Holme S. In vitro assays used in the evaluation of the quality of stored platelets: correlation with in vivo assays. Transfus Apher Sci 2008;39:161-5.
6. Rinder HM, Smith BR. In vitro evaluation of stored platelets: is there hope for predicting posttransfusion platelet survival and function? Transfusion 2003;43:2-6.
7. Cardigan R, Williamson LM. The quality of platelets after storage for 7 days. Transfus Med 2003;13:173-87.
8. Michelson AD, Barnard MR, Hechtman HB, Macgregor H, Connolly RJ, Loscalzo J, Valeri CR. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A 1996;93:11877-82.
9. Rinder HM, Snyder EL, Tracey JB, Dincecco D, Wang C, Baril L, Rinder CS, Smith BR. Reversibility of severe meta- bolic stress in stored platelets after in vitro plasma rescue or in vivo transfusion: restoration of secretory function and maintenance of platelet survival. Transfusion 2003;43: 1230-7.
10. Khuri SF, Healey N, Macgregor H, Barnard MR, Szymanski IO, Birjiniuk V, Michelson AD, Gagnon DR, Valeri CR. Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999;117:172-83.
11. Valeri CR, Macgregor H, Giorgio A, Ragno G. Circulation and hemostatic function of autologous fresh, liquidpreserved, and cryopreserved baboon platelets transfused to correct an aspirin-induced thrombocytopathy. Transfusion 2002;42:1206-16.
12. Council of Europe-European Directorate for the Quality of Medicines and HealthCare (EDQM). Guide to the preparation, use and quality assurance of blood components. 14th ed. Recommendation No. R(95)15. Strasbourg: Council of Europe Publishing; 2008.
13. Li J, de Korte D, Woolum MD, Ruane PH, Keil SD, Lockerbie O, McLean R, Goodrich RP. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technologytreated apheresis platelet products. Vox Sang 2004;87:82-90.
14. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005;45:1335-41.
15. Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns AP. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006; 90:279-85.
16. Picker SM, Steisel A, Gathof BS. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008;48:1685-92.
17. Picker SM, Steisel A, Gathof BS. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: results of a three-arm in vitro study. Transfus Apher Sci 2009;40: 79-85.
18. Picker SM, Schneider V, Gathof BS. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies. Transfusion 2009;49:1224-32.
19. Picker SM, Oustianskaia L, Schneider V, Gathof BS. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen- HCl (S-59) or riboflavin (vitamin B(2)) for pathogenreduction. Vox Sang 2009;97:26-33.
20. Larsen CP, Ezligini F, Hermansen NO, Kjeldsen-Kragh J. Six years' experience of using the BacT/ALERT system to screen all platelet concentrates, and additional testing of outdated platelet concentrates to estimate the frequency of false-negative results. Vox Sang 2005;88:93-7.
21. Svendsen MS, Rojkjaer R, Kristensen AT, Salado-Jimena JA, Kjalke M, Johansson PI. Impairment of the hemostatic potential of platelets during storage as evaluated by flow cytometry, thrombin generation, and thrombelastography under conditions promoting formation of coated platelets. Transfusion 2007;47:2057-65.
22. Bertolini F, Murphy S. A multicenter inspection of the swirling phenomenon in platelet concentrates prepared in routine practice. Biomedical Excellence for Safer Transfusion (BEST)Working Party of the International Society of Blood Transfusion. Transfusion 1996;36:128-32.
23. Enjeti AK, Lincz LF, Seldon M. Microparticles in health and disease. Semin Thromb Hemost 2008;34:683-91.
24. Gulliksson H. Defining the optimal storage conditions for the long-term storage of platelets. Transfus Med Rev 2003; 17:209-15.
25. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol 2004;25:489-95.
26. Wencel-Drake JD, Boudignon-Proudhon C, Dieter MG, Criss AB, Parise LV. Internalization of bound fibrinogen modulates platelet aggregation. Blood 1996;87:602-12.
27. Escolar G, White JG. Changes in glycoprotein expression after platelet activation: differences between in vitro and in vivo studies. Thromb Haemost 2000;83:371-86.
28. Nurden P. Bidirectional trafficking of membrane glycoproteins following platelet activation in suspension. Thromb Haemost 1997;78:1305-15.
29. Skripchenko A, Kurtz J, Moroff G, Wagner SJ. Platelet products prepared by different methods of sedimentation undergo platelet activation differently during storage. Transfusion 2008;48:1469-77.
30. Kostelijk EH, Fijnheer R, Nieuwenhuis HK, Gouwerok CW, de Korte D. Soluble P-selectin as parameter for platelet activation during storage. Thromb Haemost 1996;76: 1086-9.
31. Li J, Xia Y, Bertino AM, Coburn JP, Kuter DJ. The mechanism of apoptosis in human platelets during storage. Transfusion 2000;40:1320-9.
32. Picker SM, Schneider V, Oustianskaia L, Gathof BS. Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies. Transfusion 2009;49:2311-8.
33. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-4.
34. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001;98:1047-54.
35. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003; 92:1041-8.
36. Hassan GS, Merhi Y, Mourad WM. CD154 and its receptors in inflammatory vascular pathologies. Trends Immunol 2009;30:165-72.
37. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002;8:247-52.
38. Kaufman J, Spinelli SL, Schultz E, Blumberg N, Phipps RP. Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion. J Thromb Haemost 2007;5:788-96.